Abstract
Executive Summary
Since its discovery in 1998 by two scientists, the naturally occurring RNA
interference effect has been hailed as the hottest technical breakthrough in
biological research in the last decade. It may even surpass PCR as a top
technology. RNA interference allows scientists to silence the expression or
effect of a gene being studied. Known simply as RNAi, this field has rapidly
emerged as a fast growing new market. Much like the go-go times of 1999, VC
investments in 2003-2005 have produced a growing new crop of interesting RNAi
companies.
This report assesses this emerging commercial market and maps the players on
the market landscape. The initial companies produced reagents and kits for the
biological research reagents market to support basic and applied research in
academia, government and industry. A number of companies decided to take the
long road to develop therapeutics. Others have developed drug delivery
approaches for emerging RNAi therapeutics.
Some companies have decided to focus on offering RNAi based target validation
products or services for drug discovery or to companies like big pharmas or
biotech drug discovery firms. Other companies are trying other approaches such
as making libraries or databases of the results of their experiments. This
content or related service may help researchers see the big picture faster at
lower cost.
This research report is designed for people that include marketers, business
development, top executives, investors, VCs, consultants, R&D managers,
entrepreneurs and etc. Detailed tables or figures provide key data about items
such as strategic alliances, M&As, market size, segments and the like. This
report includes 21 company profiles that provide the reader a snapshot of the
companiesO focus or activities.
View Cart
